Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

55 results about "Prostate cancer cell line" patented technology

Application of miR-505-3p in diagnosis, prognosis and treatment of PCa (prostate cancer) bone metastasis

The invention discloses an application of miR-505-3p in diagnosis, prognosis and treatment of PCa (prostate cancer) bone metastasis. Research finds that miR-505-3p has low expression in PCa tissue ofbone metastasis and in PCa cell lines of metastasis, further, miR-505-3p is in negative correlation with N and M clinical staging and Gleason grading of PCa patients, and low expression of miR-505-3pindicates lower survival rate in bone-metastasis-free progress; besides, up-regulated miR-505-3p inhibits migration and invasion of the PCa cell lines of bone metastasis. Above all, a reagent for detecting expression quantity of miR-505-3p can be used for diagnosis and prognosis of PCa bone metastasis, and substances capable of up-regulating the expression quantity of miR-505-3p are expected to become a treatment drug for inhibiting PCa bone metastasis.
Owner:THE SECOND AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIV

Method of using pomegranate extracts for increasing prostate specific antigen doubling time

Pomegranate juice consumption by a patient may be used to treat prostate cancer. Prior to the present invention, it has been observed that various pomegranate compositions have cancer chemopreventive properties on various in vitro treatment of human prostate cancer cell lines and in vivo treatment of human prostate cancer cell lines xenografted in athymic nude mice. Until the discovery of the present invention, it was not known if there is an efficacy for treating prostate cancer in human patient by any route of administration. The present invention provides a method of treating a subject with prostate cancer a composition comprising a therapeutically effective amount of an extract from pomegranate fruit. The extract of pomegranate may be a juice extract of pomegranate, an extract from inner or outer peel of pomegranate, or mixture thereof. Pomegranate juice may be used to treat subjects with rising serum PSA after prostate surgery or radiotherapy.
Owner:POM WONDERFUL

Spontaneously immortalized prostate cancer cell line

This disclosure provides prostate cancer cell lines established from spontaneously immortalized, extremely tumorigenic and clonogenic primary prostate tumor. These cell lines represent unique cancer cell and cancer stem cell (CSC) models for preclinical prostate cancer studies and CSC-targeted drug development, which is of high value for pharmaceutic companies producing anti-cancer agents, as well as for the broad range of basic and translational research focused on cancer cell and CSC biology, stem cell behavior, cancer development and metastasis.
Owner:THE RES FOUND OF STATE UNIV OF NEW YORK

Olefinated estrogen compound as well as preparation and application thereof

The invention relates to an olefinated estrogen compound (I), a preparation method thereof and application thereof to the preparation of an antineoplastic drug. The invention has the beneficial effects which are mainly embodied in that (1), an olefinated estrogen drug provided by the invention is novel in structure, has favorable antineoplastic activity, and particularly has excellent inhibitory activity to the cell line MCF-7 of a mammary cancer and a cell line PC-7 of a prostatic cancer; and (2), a preparation method of the olefinated estrogen drug, which is provided by the invention, can beused for preparing and obtaining the olefinated estrogen drug in a high-yield manner by only needing one step, and has the characteristics of being simple, efficient, convenient and quick, and the like.
Owner:ZHEJIANG UNIV OF TECH

Amide compound and application thereof in treating cancer

The invention discloses an amide compound and an application thereof in treating cancer, and belongs to the field of pharmaceutical chemistry. The invention discloses the application of amide compoundshown in formula I, or crystal form, or stereoisomer, or isotope body, or tautomer, or pharmaceutically-acceptable salt, or solvate, or pro-drug, or metabolite thereof in treating cancer. Experimental results show that the compound can inhibit the proliferation of prostate cancer cells, especially has an obvious inhibition effect on drug-resistant prostate cancer cell line (22RV1). At the same time, the compound can obviously inhibit the proliferation of multiple cancer cells. In addition, the compound has good pharmacokinetics, which has a potential therapeutic effect on cancer, especially prostate cancer, and provides a new choice for clinical screening and / or preparation of cancer drugs.
Owner:HINOVA PHARM INC

Marker and kit for auxiliary diagnosis of prostatic cancer

The invention belongs to the technical field of medical biology, and discloses a molecular marker-LncRNA SNHG11 for auxiliary diagnosis of prostatic cancer. The LncRNA SNHG11 is highly expressed in cancer tissues of prostatic cancer, and is lowly expressed in paracancerous normal tissues; moreover, the expression level of the LncRNA SNHG11 in a prostatic cancer cell line is obviously higher than that of a normal prostate cell line; proliferation, migration and invasion of prostatic cancer cells can be obviously inhibited by knocking down the expression level of the LncRNA SNHG11 gene. Therefore, the LncRNA SNHG11 can be used as a molecular marker for auxiliary diagnosis of the prostatic cancer; by detecting the expression level of the LncRNA SNHG11 in a sample, auxiliary diagnosis can be carried out on the prostatic cancer, and a reference basis is provided for clinical doctors to diagnose the prostatic cancer.
Owner:PEOPLES HOSPITAL OF HENAN PROV

Method for Treatment of Castration-Resistant Prostate Cancer

Castrate resistant prostate cancer cell lines exhibiting resistance to the androgen-receptor antagonist enzaluatamide overexpress one or both of IGFBP-2 or IGFBP-5 when compared to non-resistant cell lines. Oligonucleotides that target IGFBP-2 and IGFBP-5 can be used to overcome this resistance or as part of a treatment program when administered concurrently with the administration of androgen-receptor antagonist treatments.
Owner:THE UNIV OF BRITISH COLUMBIA

Methods of using pvt1 exon 9 to diagnose and treat prostate cancer

PVT1 exon 9 is overexpressed in aggressively tumorigenic prostate cancer cell lines and prostate tumor tissues. This exon provides a diagnostic tool for the detection and monitoring of aggressive prostate cancer. Several small interfering ribonucleic acids (siRNAs) are disclosed that are useful for treating prostate cancer.
Owner:RES FOUND THE CITY UNIV OF NEW YORK

Application of Cephaloziellins H in preparation of prostate cancer treating medicine

The invention discloses application of Cephaloziellins H in preparation of prostate cancer treating medicine, and belongs to the field of medicine. Researches show that Cephaloziellins H has an effect of inhibiting prostate cancer cell lines PC3 and DU145, and the effect has a concentration--time dependent relation, so that Cephaloziellins H can be further developed into preparation of prostate cancer treating medicine.
Owner:刘高志

13-Cis-RAMBA RETINAMIDES THAT DEGRADE MNKs FOR TREATING CANCER

The synthesis and in vitro and in vivo anti-breast and anti-prostate cancers activities of novel C-4 heteroaryl 13-cis retinamides that modulate Mnk-eIF4E and AR signaling are discussed. In both breast and prostate cancer cell lines, these compounds induce Mnk1 / 2 degradation to substantially suppress eIF4E phosphorylation. In prostate cancer cells, the compounds induce degradation of both full-length androgen receptor (fAR) and splice variant AR (AR-V7) to inhibit AR transcriptional activity. The consequences of these multiple activities resulted in inhibition of cell growth and migration and induction of apoptosis. Finally and importantly, the compounds demonstrate strong in vitro and in vivo anti-breast and anti-prostate cancer activities, with no apparent host toxicities.
Owner:UNIV OF MARYLAND

Oligoamine compounds and derivatives thereof for cancer therapy

Oligoamine compounds with anti-cancer and anti-proliferative activity are provided, as well as methods for making and using the compounds. The compounds are shown to be active against prostate cancer cell lines and against prostate cancer tumors in mice. The compounds are also useful in treatment of breast cancer and other cancers.
Owner:PROGEN PHARMA INC

Prostatic cancer stem cell marker, application of antibody OV6 in preparation of prostatic cancer stem cell marking material and marking method

The invention relates to the field of medical technique research and discloses a prostatic cancer stem cell marker, application of an antibody OV6 in the preparation of a prostatic cancer stem cell marking material and a marking method. The marking method comprises the following steps: marking a prostate cancer cell line or a prostate tissue cell by virtue of a mouse-source OV6 antibody; incubating the prostate cancer cell line or the prostate tissue cell together with rat anti-mouse IgG and magnetic beads; putting the prostate cancer cell line or the prostate tissue cell on an MACS MS column,and carrying out filtration separation, so as to obtain an OV6 positive prostatic cancer cell; and finally detecting the marking efficiency of the OV6 positive prostatic cancer cell by virtue of a flow cytometry. Furthermore, enzalutamide is utilized for realizing drug stimulation so as to enhance the marking effect before the marking of the mouse-source OV6 antibody. According to the marking method, the prostatic cancer stem cell can be remarkably marked, and the OV6 positive cell has high expression dryness-related gene and high granulation rate and tumor formation rate. The marking methodhas relatively high specificity and sensitivity and important clinical values.
Owner:SHANGHAI CHANGHAI HOSPITAL

18beta-glycyrrhetinic acid carbamate derivative, preparation method and application thereof

InactiveCN109608513ANew structureDoes not cause high blood pressureSteroidsAntineoplastic agentsProstate cancer cellCarbamate
The invention discloses a 18beta-glycyrrhetinic acid carbamate derivative, which has a structure shown as formula (I) or (II) in the specification. The compound provided by the invention has a brand new structure, and has significant inhibitory effect on lung cancer, liver cancer, colon cancer, breast cancer and prostate cancer cell lines. And the antitumor activity of parts of the compounds is close to crizotinib.
Owner:JINZHOU MEDICAL UNIV

Pyrazolopyrimidine compound containing piperazine or its medicinal salt and preparation method and application thereof

The invention discloses a pyrazolopyrimidine compound containing piperazine or its medicinal salt. The pyrazolopyrimidine compound is characterized by comprising a following general formula Y shown asa specification, wherein R1 is hydrogen, single halogen substitute, double halogen substitute, a methoxy group or alkane; R2 is hydrogen, chlorine or bromine; and R3 is hydrogen, an amino group, a substituted amino group, substituted piperidine or a substitutedpiperazinyl group. The pyrazolopyrimidine compound containing piperazine or its medicinal salt have novel structures and are shown as thegeneral formula Y, and the introduction of a R3 group (the substituted amino group) is a necessary group for increasing the activity of the compound. Through the above design reconstruction mode, thepyrazolopyrimidine compound has AKT1 kinases inhibition activity, and prevents inhibition activity on prostate cancer cell lines (PC-3 cells).
Owner:ZUNYI MEDICAL UNIVERSITY

Lytic peptides having Anti-proliferative activity against prostate cancer cells

Lytic peptides, including fusion peptides of lytic peptides conjugated with luteinizing hormone-releasing hormone or modified versions thereof to target luteinizing hormone-releasing hormone receptors, are disclosed. The lytic peptides show anti-proliferative activity against human prostate cancer cell lines, but are nontoxic to normal primary human prostate epithelial cells or to bone marrow stromal cells in co-culture. The lytic peptides have specificity for and anti-proliferative activity against prostate cancer tumor cells, and low toxicity for normal prostate cells, making the peptides useful in therapies for prostate cancer.
Owner:TUSKEGEE UNIVERSITY

Aromatic amine protein degradation chimeric compound targeting AR and BET and application

The invention relates to an aromatic amine protein degradation chimeric compound targeting AR and BET and an application thereof, and particularly provides a compound as shown in a formula I in the description. Experimental results show that the compound can degrade AR and BRD4 in a targeted manner and reduce protein expression of the AR and the BRD4 at the same time. The compound can inhibit proliferation of various prostate cancer cells, can inhibit proliferation of a prostate cancer cell line LNCaP / AR with multiple expression of an androgen receptor AR, and also shows a good inhibition effect on prostate cancer cell lines 22RV1 resistant to prostate cancer drugs (enzalutamide) on the market. The compound also shows good metabolic stability, and has good application prospects in preparation of androgen receptor and / or BET protein degradation targeting chimeras and drugs for treating androgen receptor and BET regulated related diseases.
Owner:HINOVA PHARM INC

Hybrid-ionone and curcumin molecules as anticancer agents

The present invention relates to the synthesis of a series of ionone and curcumin derivatives as multi-targeting agents effective against both hormone-sensitive and hormone-independent cancers. In particular, the present invention is directed to a distinct class of bifunctional antiandrogens, which inhibit both AR and IKBkinases (IKK). A series of ionone-based chalcones were synthesized and their in vitro cytotoxicity against prostate cancer cell lines were demonstrated. A series of derivatives formed by reacting ionone-based chalcones and hydrazines demonstrate substantial antiproliferative activities in prostate cancer, breast cancer and lung cancer cell lines.
Owner:TRT PHARMA

Aromatic amine compound and application thereof in preparation of AR and BRD4 dual inhibitors and regulators

The invention relates to an aromatic amine compound and application thereof in the preparation of AR and BRD4 dual inhibitors and regulators. Specifically, the invention provides a compound shown as aformula I, and the compound has dual inhibition effects on AR and BRD4. The compound not only can inhibit proliferation of prostate cancer cell lines LNCaP / AR with multiple expression of androgen receptor AR, but also shows a good inhibition effect on prostate cancer cell lines VCaP and 22RV1, which are resistant to prostate cancer drugs (enzalutamide) on the market. The compound is used as a compound capable of simultaneously identifying AR and BRD4 double targets; can be used as an AR / BRD4 dual inhibitor, can also be used for preparing protein degradation targeting chimeras (PROTACs) for inducing AR / BRD4 dual-target degradation, and has a good application prospect in preparation of drugs for treating AR and BRD4 related diseases.
Owner:HINOVA PHARM INC

Dock Derived Compound against Laminin Receptor (37 LR) and Uses thereof

An in silico screening method generated compounds that are against laminin receptor 37 LR and their anti-cancer functions in prostate cancer cell lines are disclosed herein. A group of derivatives based on the hit compound from the in silico screening are synthesized and tested with improved IC50 value that can have relevant clinical use for prostate cancer or osteoarthritis.
Owner:PURDUE RES FOUND INC

Oligoamine compounds and derivatives thereof for cancer therapy

Oligoamine compounds with anti-cancer and anti-proliferative activity are provided, as well as methods for making and using the compounds. The compounds are shown to be active against prostate cancer cell lines and against prostate cancer tumors in mice. The compounds are also useful in treatment of breast cancer and other cancers.
Owner:PROGEN PHARMA INC

Small molecule inhibitors for early diagnosis of prostate specific membrane antigen cancers and neurodegenerative diseases

Accordingly, embodiments herein disclose a compound and method of small molecule inhibitors or ligands for diagnosis and treatment of cancers such as prostate, brain, breast, etc., and neurodegenerative diseases. A new class of PSMA inhibitors called as aminoacetamide, 1, has been designed by extensive in silico studies. A simple, mild and high yielding synthetic methodology is developed for 1 and shown to have high affinity for PSMA protein. Fluorescent conjugates 22 and 25 derived from 1 show selective uptake in prostate cancer cell lines and can be used for surgical removal of tumors during intra-operative surgery. Conjugates 31 and 34 for tagging 99mTc radioisotope were synthesized. Macrocyclic chelating cores such as DOTA, NOTA or prosthetic groups can be introduced to tag radionuclides 68Ga, 64Cu, 18F and 177Lu for diagnosis and treatment of PCa, incurable mCRPC and neurodegenerative diseases such as ALS, schizophrenia and neuropathic pain that over-express PSMA protein.
Owner:INDIAN INST OF TECH INDORE

Method for treatment of castration-resistant prostate cancer

Castrate resistant prostate cancer cell lines exhibiting resistance to the androgen-receptor antagonist enzaluatamide overexpress one or both of IGFBP-2 or IGFBP-5 when compared to non-resistant cell lines. Oligonucleotides that target IGFBP-2 and IGFBP-5 can be used to overcome this resistance or as part of a treatment program when administered concurrently with the administration of androgen-receptor antagonist treatments.
Owner:THE UNIV OF BRITISH COLUMBIA

Prostate cancer cell lines and their use in screening method

The present invention relates to a prostate cancer cell line CNCM deposit number I-4126, the use thereof for preparing resistant prostate cancer cell lines, the resistant prostate cancer cell lines, and the use of these prostate cancer cell lines for screening compounds of interest.
Owner:INSTITUT GUSTAVE ROUSSY

Anti-cxadr antibody

ActiveUS20150140018A1Excellent in vivo anti-cancer activityLibrary screeningBiological material analysisProstate cancer cellAnticarcinogen
An object is to find a target molecule effective for cancer treatments and the like and to provide an antibody capable of specifically binding to the molecule, an anticancer agent comprising the antibody as an active ingredient, and so forth. Hence, prostate cancer cell lines (LNCaP-CR cells and LNCaP cells) were compared by SST-REX, and CXADR was identified as a molecule involved in tumor formation and so on. Then, a monoclonal antibody against CXADR was prepared, and the anti-cancer activity, ADCC activity, CDC activity, and so forth were examined. The result revealed that an antibody capable of binding to an epitope present at positions 181 to 230 of a CXADR protein derived from human exhibited an anti-cancer activity against prostate cancer cells, pancreatic cancer cells, and colorectal cancer cells. Further, it was also revealed that the antibody had an ADCC activity and a CDC activity. Moreover, the structures of light chain and heavy chain variable regions of the antibody were successfully determined.
Owner:MICROBIAL CHEM RES FOUND +1

Olefinated ethinyloestradiol compound, and preparation and application thereof

The invention relates to an olefinated ethinyloestradiol compound with good anti-tumor activity, and a preparation method and application thereof. The olefinated ethinyloestradiol compound has the beneficial effects mainly shown in that (1) an ethinyloestradiol drug with modified different sites is novel in structure, has the good anti-tumor activity, and has excellent inhibitory activity especially for a human prostate cancer cell line PC-3 and breast cancer cells MCF-7; and (2) the most suitable olefination modification sites of the ethinyloestradiol drug are provided through screening, andthe foundation is laid for modification of the ethinyloestradiol drug.
Owner:ZHEJIANG UNIV OF TECH

A kind of olefinated estrogen compound and its preparation and application

The invention relates to an olefinated estrogen compound (I), a preparation method thereof and application thereof to the preparation of an antineoplastic drug. The invention has the beneficial effects which are mainly embodied in that (1), an olefinated estrogen drug provided by the invention is novel in structure, has favorable antineoplastic activity, and particularly has excellent inhibitory activity to the cell line MCF-7 of a mammary cancer and a cell line PC-7 of a prostatic cancer; and (2), a preparation method of the olefinated estrogen drug, which is provided by the invention, can beused for preparing and obtaining the olefinated estrogen drug in a high-yield manner by only needing one step, and has the characteristics of being simple, efficient, convenient and quick, and the like.
Owner:ZHEJIANG UNIV OF TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products